207 related articles for article (PubMed ID: 27221238)
1. Human papillomavirus infection in Rwanda at the moment of implementation of a national HPV vaccination programme.
Ngabo F; Franceschi S; Baussano I; Umulisa MC; Snijders PJ; Uyterlinde AM; Lazzarato F; Tenet V; Gatera M; Binagwaho A; Clifford GM
BMC Infect Dis; 2016 May; 16():225. PubMed ID: 27221238
[TBL] [Abstract][Full Text] [Related]
2. Human papillomavirus vaccine effect against human papillomavirus infection in Rwanda: evidence from repeated cross-sectional cervical-cell-based surveys.
Sayinzoga F; Tenet V; Heideman DAM; Sibomana H; Umulisa MC; Franceschi S; Hakizimana JD; Clifford GM; Baussano I
Lancet Glob Health; 2023 Jul; 11(7):e1096-e1104. PubMed ID: 37207683
[TBL] [Abstract][Full Text] [Related]
3. Screening for human papillomavirus, cervical cytological abnormalities and associated risk factors in HIV-positive and HIV-negative women in Rwanda.
Mukanyangezi MF; Sengpiel V; Manzi O; Tobin G; Rulisa S; Bienvenu E; Giglio D
HIV Med; 2018 Feb; 19(2):152-166. PubMed ID: 29210158
[TBL] [Abstract][Full Text] [Related]
4. Human papillomavirus infection in Bhutan at the moment of implementation of a national HPV vaccination programme.
Tshomo U; Franceschi S; Dorji D; Baussano I; Tenet V; Snijders PJ; Meijer CJ; Bleeker MC; Gheit T; Tommasino M; Clifford GM
BMC Infect Dis; 2014 Jul; 14():408. PubMed ID: 25047665
[TBL] [Abstract][Full Text] [Related]
5. Baseline prevalence and type distribution of human papillomavirus in healthy Chinese women aged 18-25 years enrolled in a clinical trial.
Zhao FH; Zhu FC; Chen W; Li J; Hu YM; Hong Y; Zhang YJ; Pan QJ; Zhu JH; Zhang X; Chen Y; Tang H; Zhang H; Durand C; Datta SK; Struyf F; Bi D;
Int J Cancer; 2014 Dec; 135(11):2604-11. PubMed ID: 24740547
[TBL] [Abstract][Full Text] [Related]
6. Prevaccination distribution of human papillomavirus types in women attending at cervical cancer screening in Belgium.
Arbyn M; Benoy I; Simoens C; Bogers J; Beutels P; Depuydt C
Cancer Epidemiol Biomarkers Prev; 2009 Jan; 18(1):321-30. PubMed ID: 19124515
[TBL] [Abstract][Full Text] [Related]
7. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
8. Type-specific HPV prevalence in invasive cervical cancer in the UK prior to national HPV immunisation programme: baseline for monitoring the effects of immunisation.
Mesher D; Cuschieri K; Hibbitts S; Jamison J; Sargent A; Pollock KG; Powell N; Wilson R; McCall F; Fiander A; Soldan K
J Clin Pathol; 2015 Feb; 68(2):135-40. PubMed ID: 25410654
[TBL] [Abstract][Full Text] [Related]
9. Persistence rate of cervical human papillomavirus infections and abnormal cytology in Rwanda.
Mukanyangezi MF; Rugwizangoga B; Manzi O; Rulisa S; Hellstrand K; Tobin G; Martner A; Bienvenu E; Giglio D
HIV Med; 2019 Aug; 20(7):485-495. PubMed ID: 31318136
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
11. Long-term human papillomavirus vaccination effectiveness and immunity in Rwandan women living with and without HIV: a study protocol.
Murenzi G; Shumbusho F; Hansen N; Munyaneza A; Gage JC; Muhoza B; Kanyabwisha F; Pierz A; Tuyisenge P; Anastos K; Castle PE
BMJ Open; 2022 Aug; 12(8):e061650. PubMed ID: 36008069
[TBL] [Abstract][Full Text] [Related]
12. Cervical high-risk human papillomavirus infection among women residing in the Gulf Cooperation Council countries: Prevalence, type-specific distribution, and correlation with cervical cytology.
Ali MAM; Bedair RN; Abd El Atti RM
Cancer Cytopathol; 2019 Sep; 127(9):567-577. PubMed ID: 31390155
[TBL] [Abstract][Full Text] [Related]
13. Distribution of Human Papillomavirus (HPV) Genotypes in HIV-Negative and HIV-Positive Women with Cervical Intraepithelial Lesions in the Eastern Cape Province, South Africa.
Taku O; Mbulawa ZZA; Phohlo K; Garcia-Jardon M; Businge CB; Williamson AL
Viruses; 2021 Feb; 13(2):. PubMed ID: 33670231
[TBL] [Abstract][Full Text] [Related]
14. Human papillomavirus genotypes in cervical and other HPV-related anogenital cancer in Rwanda, according to HIV status.
Mpunga T; Chantal Umulisa M; Tenet V; Rugwizangoga B; Milner DA; Munyanshongore C; Heideman DAM; Bleeker MCG; Tommasino M; Franceschi S; Baussano I; Gheit T; Sayinzoga F; Clifford GM
Int J Cancer; 2020 Mar; 146(6):1514-1522. PubMed ID: 31173641
[TBL] [Abstract][Full Text] [Related]
15. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
Muñoz N; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; Garcia PJ; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Huh WK; Joura EA; Kurman RJ; Majewski S; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Lupinacci LC; Giacoletti KE; Sings HL; James MK; Hesley TM; Barr E; Haupt RM
J Natl Cancer Inst; 2010 Mar; 102(5):325-39. PubMed ID: 20139221
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of prophylactic HPV vaccines against cervical abnormalities and HPV infection in Japan: The J-HERS 2021 multicenter study.
Saeki Y; Saito M; Irie T; Itoh F; Enatsu A; Komura H; Fujii M; Fujii R; Hidaka N; Maehama T; Shirasu N; Waseda T; Shibata T; Takada E; Mibe K; Sakamoto J; Yamada S; Takakura M; Sasagawa T
J Med Virol; 2024 Feb; 96(2):e29413. PubMed ID: 38314927
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
[TBL] [Abstract][Full Text] [Related]
18. Early effect of bivalent human papillomavirus vaccination on cytology outcomes in cervical samples among young women in the Netherlands.
Schurink-van 't Klooster TM; Siebers AG; Hoes J; van Kemenade FJ; Berkhof J; Bogaards JA; de Melker HE
Cancer Med; 2023 May; 12(10):11786-11794. PubMed ID: 36965085
[TBL] [Abstract][Full Text] [Related]
19. National experience in the first two years of primary human papillomavirus (HPV) cervical screening in an HPV vaccinated population in Australia: observational study.
Smith MA; Sherrah M; Sultana F; Castle PE; Arbyn M; Gertig D; Caruana M; Wrede CD; Saville M; Canfell K
BMJ; 2022 Mar; 376():e068582. PubMed ID: 35354610
[TBL] [Abstract][Full Text] [Related]
20. HPV infections and cytologic abnormalities in vaccinated women 21-34 years of age: Results from the baseline phase of the Onclarity trial.
Wright TC; Parvu V; Stoler MH; Kodsi S; Eckert K; Yanson K; Cooper CK
Gynecol Oncol; 2019 May; 153(2):259-265. PubMed ID: 30853359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
